A phase III trial of CHOP [cyclophosphamide, doxorubicin, vincristine and prednisone] plus rituximab vs CHOP plus iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-Hodgkin's lymphomas.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 20 Aug 2018
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 13 Jul 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2023.
- 22 Jan 2018 Long-term follow-up results published in the Journal of Clinical Oncology
- 13 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Jun 2018.